(Total Views: 577)
Posted On: 06/03/2025 11:57:46 AM
Post# of 154604
I was looking into how CYDY could market LL for multiple indications to multiple BPs. Came across this article on how to value biotechs as the indication moves through the phases of approvals.
The company has a lot going for it; some news of pre-clinical upside surprises would be nice kickers as they try to navigate the values of potential partnerships or BO offers.
Fun read.
ETA: another interesting take: https://pmc.ncbi.nlm.nih.gov/articles/PMC8854317/
The company has a lot going for it; some news of pre-clinical upside surprises would be nice kickers as they try to navigate the values of potential partnerships or BO offers.
Fun read.
ETA: another interesting take: https://pmc.ncbi.nlm.nih.gov/articles/PMC8854317/
(2)
(0)
